| Autor: |
Simion L; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Oncological Surgery I, Bucharest Oncological Institute, 022328 Bucharest, Romania., Chitoran E; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Oncological Surgery I, Bucharest Oncological Institute, 022328 Bucharest, Romania., Cirimbei C; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Oncological Surgery I, Bucharest Oncological Institute, 022328 Bucharest, Romania., Stefan DC; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania., Neicu A; Department of Pathology, Bucharest Oncological Institute, 022328 Bucharest, Romania., Tanase B; Department of Thoracic Surgery, Bucharest Oncological Institute, 022328 Bucharest, Romania., Ionescu SO; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Oncological Surgery I, Bucharest Oncological Institute, 022328 Bucharest, Romania., Luca DC; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Oncological Surgery I, Bucharest Oncological Institute, 022328 Bucharest, Romania., Gales L; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Medical Oncology, Bucharest Oncological Institute, 022328 Bucharest, Romania., Gheorghe AS; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Medical Oncology, Bucharest Oncological Institute, 022328 Bucharest, Romania., Stanculeanu DL; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Medical Oncology, Bucharest Oncological Institute, 022328 Bucharest, Romania., Rotaru V; Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Department of Oncological Surgery I, Bucharest Oncological Institute, 022328 Bucharest, Romania. |
| Abstrakt: |
The aim of our study is to present the particularities of a specific subset of gynecological cancer patients in Romania. We present a review of synchronous gynecological neoplasia (SGN) treated in the Bucharest Oncological Institute's surgery departments over a decade. Between 2012 and 2022, 7419 female patients with genital malignancies were treated. We identified 36 patients with invasive synchronous primary gynecological cancers (0.5%) and 12 cases with one primary gynecological and another primary invasive pelvic cancer (rectal/bladder). All recurrent, metastatic, or metachronous tumors detected were excluded. Demographic data, personal history, presenting symptoms, pathologic findings, staging, treatment, and evolution for each case were recorded. Usually, the most common SGN association is between ovarian and endometrial cancer of endometrioid differentiation (low-grade malignancies with very good prognosis). However, we noticed that, given the particularities of the Romanian medical system, the most frequent association is between cervical and endometrial, followed by cervical and ovarian cancers. Moreover, the cancer stage at diagnosis is more advanced. In countries with low HPV vaccination rate and low adherence to screening programs, SGNs can present as extremely advanced cases and require extensive surgery (such as pelvic exenterations) to achieve radicality. This multimodal treatment in advanced cases with high tumor burden determines a reduction in survival, time until progression, and quality of life. |
